The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia
ABSTRACT Asparaginase and methotrexate (MTX), both essential for pediatric acute lymphoblastic leukemia therapy, are often used concomitantly. Depending on the sequence, in vitro, asparaginase inhibits MTX-polyglutamate (MTXPG) formation, and side effects overlap. MTX toxicity and efficacy, reflected by intracellular erythrocyte MTXPG’s, were compared between children treated with and without asparaginase during high dose MTX (HD-MTX) courses of the DCOG ALL-11 protocol (NL50250.078.14). Seventy-three patients, of whom 23 received asparaginase during the HDMTX courses, were included. Grade 3–4 leukopenia and neutropenia occurred more often (59% and 86% vs. 30% and 62%). The number of infections, grade 3–4 hepatotoxicity, nephrotoxicity, and neurotoxicity did not differ. Patients with asparaginase had lower MTXPG levels, although to a lesser extent than in vitro studies. Although patients with asparaginase during HD-MTX courses showed more myelosuppression, this had no (serious) clinical consequences. Regarding the MTX efficacy, the schedule-related antagonism seen in in vitro seems less important in vivo.
|Persistent URL||dx.doi.org/10.1080/10428194.2019.1613537, hdl.handle.net/1765/116985|
|Journal||Leukemia and Lymphoma|
Kloos, R.Q.H., Pieters, R, van den Bos, C, van Eijkelenburg, N.K.A., de Jonge, R., & van der Sluis, I.M. (2019). The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia. Leukemia and Lymphoma. doi:10.1080/10428194.2019.1613537